Antimicrobial drug development--the past, the present, and the future
- PMID: 15522037
- DOI: 10.1111/j.1465-0691.2004.1007.x
Antimicrobial drug development--the past, the present, and the future
Abstract
Antimicrobial resistance has been an issue since the introduction into clinical use of the first agents in the 1940s. Although the discovery and development of new classes of antimicrobials through the 1960s presented an array of treatment options, these options for some serious and life-threatening infectious diseases may now be more limited. This paper examines the history of antimicrobial development, showing how the challenges in discovering new classes of drugs have been with us for the last 40 years. The present state of antimicrobial discovery and development is shaped by these challenges as well as by the economic realities of the pharmaceutical industry. This paper also discusses some of the regulatory considerations in antimicrobial drug development, and presents some potential solutions to the challenges inherent in antimicrobial drug development, including steps taken by the US Food and Drug Administration to streamline the drug review process for antimicrobial agents while maintaining the standards necessary to protect and promote the health of the public.
Similar articles
-
Trends in antimicrobial drug development: implications for the future.Clin Infect Dis. 2004 May 1;38(9):1279-86. doi: 10.1086/420937. Epub 2004 Apr 14. Clin Infect Dis. 2004. PMID: 15127341
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Antibacterial drug discovery in the 21st century.Clin Microbiol Infect. 2004 Nov;10 Suppl 4:10-7. doi: 10.1111/j.1465-0691.2004.1005.x. Clin Microbiol Infect. 2004. PMID: 15522035 Review.
-
Antibacterial discovery and development--the failure of success?Nat Biotechnol. 2006 Dec;24(12):1497-503. doi: 10.1038/nbt1206-1497. Nat Biotechnol. 2006. PMID: 17160049
-
Antibacterial drug discovery--then, now and the genomics future.Biochem Pharmacol. 2006 Mar 30;71(7):901-9. doi: 10.1016/j.bcp.2005.11.023. Epub 2006 Feb 21. Biochem Pharmacol. 2006. PMID: 16494849 Review.
Cited by
-
Acyldepsipeptide Analogues: A Future Generation Antibiotics for Tuberculosis Treatment.Pharmaceutics. 2022 Sep 15;14(9):1956. doi: 10.3390/pharmaceutics14091956. Pharmaceutics. 2022. PMID: 36145704 Free PMC article. Review.
-
New marine-derived indolymethyl pyrazinoquinazoline alkaloids with promising antimicrobial profiles.RSC Adv. 2020 Aug 21;10(52):31187-31204. doi: 10.1039/d0ra05319h. eCollection 2020 Aug 21. RSC Adv. 2020. PMID: 35520644 Free PMC article.
-
Antimicrobial Resistance of Listeria monocytogenes Strains Isolated from Humans, Animals, and Food Products in Russia in 1950-1980, 2000-2005, and 2018-2021.Antibiotics (Basel). 2021 Oct 4;10(10):1206. doi: 10.3390/antibiotics10101206. Antibiotics (Basel). 2021. PMID: 34680788 Free PMC article.
-
Signal Biosynthesis Inhibition with Ambuic Acid as a Strategy To Target Antibiotic-Resistant Infections.Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00263-17. doi: 10.1128/AAC.00263-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28607020 Free PMC article.
-
Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution?Pharmacogn Rev. 2017 Jul-Dec;11(22):57-72. doi: 10.4103/phrev.phrev_21_17. Pharmacogn Rev. 2017. PMID: 28989242 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous